The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1444
Sublingual Immunotherapy for Allergic Rhinitis
The full article is available to subscribers Subscriber Login   

The FDA has approved 3 allergen extracts for sublingual administration as immunotherapy for allergic rhinitis confirmed by a positive skin test or in vitro testing for pollen-specific IgE antibodies: Oralair (Stallergenes S.A./Greer) and Grastek (Merck) for grass pollen-induced allergic rhinitis and Ragwitek (Merck) for short ragweed pollen-induced allergic rhinitis.

ALLERGIC RHINITIS — Orally administered second-generation H1-antihistamines are the preferred first-line therapy for relief of itching, sneezing, and rhinorrhea associated with mild to moderate allergic rhinitis. Intranasal corticosteroids are the most effective drugs available for prevention and relief of allergic rhinitis symptoms, including itching, sneezing, discharge, and congestion, and are the drugs of choice for moderate to severe disease. ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Sublingual Immunotherapy for Allergic Rhinitis
Article code: 1444c
 Electronic, downloadable article - $25